Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma

Fig. 8

33% of women aged 45 < X < 50 have a deletion as the dominant BRF2 alteration in metastatic breast cancer. The cBioPortal houses two metastatic breast cancer data sets, The Metastatic Breast Cancer Project (Provisional, October 2018) [44] and Metastatic Breast Cancer (INSERM, PLoS Med 2016) [43]. A query of the metastatic breast cancer data sets, 396 patients, for BRF2 alterations was performed and (a) OncoPrint of BRF2 alterations indicates 17% (68 of 396 patients) of metastatic breast cancer patients analyzed have BRF2 alterations and the alterations are predominantly amplifications. Top track is color coded and denotes study of origin. (b) Summary of BRF2 alterations by breast cancer type. OncoPrint analysis of BRF2 alterations by age of primary breast cancer diagnosis grouped in 5-year intervals: (c) 35 < x < 40, (d) 40 < x < 45, (e) 45 < x < 50, (f) 50 < x < 55, (g) and 55 < x < 60. Red denotes amplification, blue represents deletions, and green indicates a mutation (H) Analysis of BRF2 and MYC alterations and tendency for co-occurrence, by age. P-Value and adjusted q-values are noted. Red denotes amplification, blue represents deletions, and green indicates a mutation. Metastatic breast cancer data sets analyzed are available at the cBioPortal (www.cbioportal.org). Queries of the cBioPortal were performed in September 2019, October 2019, November 2019, January 2020, February 2020, and March 2020

Back to article page
\